In a filing to the BSE, the company cited all the requisite approvals have been received for the merger of Ranbaxy into Sun Pharma effective from the appointed date of April 1, 2014.

It further added the approvals received from the respective High Courts have been filed by Ranbaxy and Sun Pharma with the respective Registrar of Companies on Tuesday.


"With these filings the merger of Ranbaxy into Sun Pharma has been consummated," the company informed.

Read more : Sun gets RBI nod for transfer of Ranbaxy overseas investments

In April, 2014, Sun Pharma had announced it would acquire troubled rival Ranbaxy in an all-stock transaction worth USD 4-billion that includes USD 800 million debt. The merger would create India's largest and the world's fifth largest drugmaker.

Read more : FTC passes final order in USD 4 billion Sun-Ranbaxy deal

Earlier in the day, Sun Pharma had announced receipt of RBI nod for transfer of overseas investments of Ranbaxy to it and issue its shares to the non-resident shareholders of the
latter as part of their merger deal.

Read more : Ranbaxy loses approvals, exclusivity of 2 drugs in US

The Reserve Bank of India on Monday also gave approval for transfer of overseas investments held by Ranbaxy in its joint venture and wholly owned-subsidiaries to Sun Pharma,

Read more : Sun-Ranbaxy deal: US FTC asks Ranbaxy to divest asset

pursuant to the proposed merger of Ranbaxy with Sun Pharma through a Scheme of Arrangement.

The central bank also approved issue of equity shares of Sun Pharma to the non-resident holders of equity shares of Ranbaxy Laboratories, the filing added.

Latest News  from Business News Desk